Longevity Medicine
What Is the APOE Gene?
Last reviewed: May 2026 · Haute MD Editorial Team
The APOE (apolipoprotein E) gene is the strongest common genetic risk factor for late-onset Alzheimer's disease. It has three common alleles — e2, e3, and e4 — and the e4 variant substantially increases lifetime Alzheimer's risk in a dose-dependent way. Knowing your APOE genotype can inform aggressive prevention but is not deterministic.
APOE alleles and risk
Three common APOE alleles exist: e2 (rare, ~7% of population), e3 (most common, ~78%), and e4 (~15%). Combinations produce six genotypes. Compared to the most common e3/e3 baseline: e3/e4 (one e4 copy, ~20-25% of the population) increases Alzheimer's risk roughly 3-4 fold; e4/e4 (~2% of the population) increases risk roughly 8-12 fold and lowers average age of onset by 5-10 years. e2 is protective — e2/e3 and e2/e2 are associated with reduced Alzheimer's risk and later onset. APOE4 also modestly increases cardiovascular disease risk and affects lipid metabolism. Importantly, APOE4 is a risk factor, not a determinant — many e4 carriers never develop Alzheimer's, and many non-carriers do. Lifetime Alzheimer's risk in e4/e4 individuals is estimated around 50-60%, not 100%.
Why knowing APOE matters
Knowing genotype enables more aggressive and individualized prevention. APOE4 carriers benefit disproportionately from cardiovascular risk reduction, exercise, and Mediterranean-style diet. APOE4 carriers are also at higher risk for ARIA (amyloid-related imaging abnormalities) from the new anti-amyloid antibody therapies, which affects treatment risk-benefit discussions if MCI develops. Some longevity practices use APOE genotype to guide screening intensity (earlier and more frequent cognitive testing, consideration of plasma p-tau or amyloid PET surveillance starting at 55-60 in homozygotes). Knowing genotype can motivate prevention adherence in some patients but cause anxiety in others — counseling is important. Direct-to-consumer testing (23andMe, others) provides genotype but without genetic counseling support.
How to think about APOE results
(1) APOE4 is a risk factor, not a diagnosis — many carriers never develop dementia; (2) Lifestyle and cardiovascular factors interact with genotype — aggressive prevention is most beneficial in carriers; (3) APOE4 carriers should particularly prioritize: blood pressure <130/80, exercise (aerobic plus resistance), Mediterranean-pattern diet, omega-3 adequacy, treating sleep apnea, treating hearing loss, social and cognitive engagement, limited alcohol, and adequate sleep; (4) APOE genotype does not generally indicate need for treatment in cognitively normal individuals — current disease-modifying therapies are only approved for symptomatic Alzheimer's; (5) Family members do not automatically share genotype — siblings have ~50% chance of inheriting the same allele combination, but each child receives only one parental allele; (6) Discuss insurance implications — GINA protects health insurance but not life or long-term care insurance. The pragmatic stance is: testing is most useful when results will change behavior, and the response to APOE4 carrier status should be aggressive evidence-based prevention, not despair or fatalism.
Frequently Asked Questions
Should I test my APOE genotype?
Reasonable for adults interested in personalized cognitive longevity planning, particularly those with family history. Testing should ideally be preceded by counseling about implications and not done casually given the psychological weight of an e4/e4 result. 23andMe and similar provide results without counseling support.
If I'm APOE4 positive, will I get Alzheimer's?
No. Lifetime risk is elevated — roughly 25-50% for e3/e4 and 50-60% for e4/e4 — but many carriers never develop dementia. Lifestyle and cardiovascular factors substantially modify outcomes, and the benefit of prevention is amplified in carriers.
Does APOE2 mean I'm protected?
e2 is associated with reduced Alzheimer's risk and later onset, but not zero risk. e2 also has some negative effects (higher triglycerides, occasional type III hyperlipoproteinemia). Carriers should still prioritize cardiovascular and cognitive health.
Does APOE affect life insurance underwriting?
It can. GINA protects health insurance and employment but not life, long-term care, or disability insurance. This is a real consideration in deciding whether and when to test, particularly for patients without coverage already in place.
Get Help Now
Speak with a Haute MD Longevity Medicine physician
Dr. George Kaltner
CEO
Longevity Medicine · Miami Beach, FL
View Profile
Dr. Alexander Golberg
Longevity Medicine · New York, NY
View Profile
Dr. Steven Victor
Regenerative Medicine Specialist
Longevity Medicine · New York, NY
View ProfileAre you a Longevity Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · LONGEVITY MEDICINE
What Is Alzheimer's Prevention?
Alzheimer's prevention targets modifiable risk factors — cardiovascular health, sleep, exercise, hearing — that account for ~40% of dementia risk.
Read GuideGuide · LONGEVITY MEDICINE
What Is MCI (Mild Cognitive Impairment)?
Mild cognitive impairment (MCI) is measurable cognitive decline beyond normal aging without functional disability — a key window for intervention.
Read GuideGuide · LONGEVITY MEDICINE
What Is Cognitive Reserve?
Cognitive reserve is the brain's capacity to tolerate pathology before symptoms appear — built by education, occupation, and lifelong cognitive engagement.
Read Guide